Using complementary and alternative medicines to target the host response during severe influenza

Evidence-based Complementary and Alternative Medicine

Volumn 7, Issue 4, 2010, Pages 501-510

  Alleva, Lisa M ^a   Cai, Charles ^b   Clark, Ian A ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b Professional Centre   (Australia)

Author keywords

High Mobility Group Box 1 protein; inflammatory response; red clover; traditional Chinese medicine

Indexed keywords

ANGELICA SINENSIS EXTRACT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTIVIRUS AGENT; ARTEMISININ; BIOCHANIN A; CHINESE DRUG; CHLOROQUINE; CYTOKINE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLYCYRRHIZIC ACID; HIGH MOBILITY GROUP B1 PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; ISOFLAVONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; SALVIA MILTIORRHIZA EXTRACT; UNCLASSIFIED DRUG; YIQI QINGWEN JIEDU HEJI;

ACUPUNCTURE; ALTERNATIVE MEDICINE; ANGELICA SINENSIS; ANTIINFLAMMATORY ACTIVITY; APTITUDE; CARDIOVASCULAR DISEASE; CHINESE HERB; CHRONIC PANCREATITIS; DEATH; DRUG USE; ENDOTOXEMIA; EXPERIMENTAL ANIMAL; FOWL; GINSENG; HUMAN; HYPERLIPIDEMIA; IMMUNE RESPONSE; IMMUNITY; INFECTION; INFLAMMATION; INFLUENZA; INFLUENZA VIRUS A H5N1; LETHALITY; LIGHT; MENOPAUSAL SYNDROME; MENOPAUSE; METHODOLOGY; MORTALITY; NONHUMAN; PANCREATITIS; PEROXISOME; PRIORITY JOURNAL; RED CLOVER; REVIEW; SALVIA; SALVIA MILTIORRHIZA; SEPSIS; UNIVERSITY;

EID: 77955001588     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nep152     Document Type: Review

References (116)

1. Clark IA, Alleva LM, Mills AC, Cowden WB. Pathogenesis of malaria and clinically similar conditions. Clin Microbiol Rev 2004;17:509-539
2. Clark IA, Budd AC, Alleva LM, Cowden WB. Human malarial disease: a consequence of inflammatory cytokine release. Malar J 2006;5:85.
3. Clark IA, Virelizier JL, Carswell EA, Wood PR. Possible importance of macrophage-derived mediators in acute malaria. Infect Immun 1981;32:1058-1066
4. Clark IA. Suggested importance of monokines in pathophysiology of endotoxin shock and malaria. Klin Wochenschr 1982;60:756-758
5. Clark IA, Cowden WB. Is TNF a key to acute infectious illness? Today's Life Science 1989;1:26-29
6. Clark IA. The advent of the cytokine storm. Immunol Cell Biol 2007;85:271-273
7. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, et al. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002;360:1831-1837
8. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006;12:1203-1207
9. To KF, Chan PK, Chan KF, Lee WK, Lam WY, Wong KF, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 2001;63:242-246
10. Hampton T. Virulence of 1918 influenza virus linked to inflammatory innate immune response. JAMA 2007;297:580.
11. Kash JC, Tumpey TM, Proll SC, Carter V, Perwitasari O, Thomas MJ, et al. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature 2006;443:578-581
12. Kobasa D, Jones SM, Shinya K, Kash JC, Copps J, Ebihara H, et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007;445:319-323
13. Booy R, Brown LE, Grohmann GS, Macintyre CR. Pandemic vaccines: promises and pitfalls. Med J Aust 2006;185:S62-5.
14. Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis 2006;1:S119-26.
15. Rainsford KD. Influenza ("Bird Flu"), inflammation and anti- inflammatory/analgesic drugs. Inflammopharmacology 2006;14:2-9.
16. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006;43:199-205.
17. Budd A, Alleva L, Alsharifi M, Koskinen A, Smythe V, Mullbacher A, et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007;51: 2965-2968
18. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsa- turated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997;94:4312-4317
19. Issemann I, Prince RA, Tugwood JD, Green S. The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol 1993;11:37-47.
20. Zhao SP, Ye HJ, Zhou HN, Nie S, Li QZ. Gemfibrozil reduces release of tumor necrosis factor-alpha in peripheral blood mono- nuclear cells from healthy subjects and patients with coronary heart disease. Clin Chim Acta 2003;332:61-67
21. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res 2000;49:497-505.
22. Cunard R, Ricote M, DiCampli D, Archer DC, Kahn DA, Glass CK, et al. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J Immunol 2002;168: 2795-2802
23. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 2008;8:571-576
24. Simon A, Fah J, Haller O, Staeheli P. Interferon-regulated Mx genes are not responsive to IL-1, TNF, and other cytokines. J Virol 1991;65:968-971
25. Van Campen H. Influenza A virus replication is inhibited by tumor necrosis factor-alpha in vitro. Arch Virol 1994;136:439-446
26. Peper RL, Van Campen H. Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia. Microb Pathog 1995;19:175-183
27. Salomon R, Hoffmann E, Webster RG. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci USA 2007;104:12479-12481
28. Quan FS, Compans RW, Cho YK, Kang SM. Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection. Vaccine 2007;25:272-282
29. Hsu CH, Hwang KC, Chao CL, Chang SG, Ho MS, Chou P. Can herbal medicine assist against avian flu? Learning from the experience of using supplementary treatment with Chinese medicine on SARS or SARS-like infectious disease in 2003. J Altern Complement Med 2006;12:505-506
30. Hsu CH, Hwang KC, Chao CL, Chang SG, Ker CC, Chien LC, et al. The lesson of supplementary treatment with Chinese medicine on severe laboratory-confirmed SARS patients. Am J Chin Med 2006;34:927-935
31. Wang X, Jia W, Zhao A. Anti-influenza agents from plants and traditional Chinese medicine. Phytother Res 2006;20:335-341
32. Wang CX, Gao GX, Wei SC, Xu HR. The dynamic effect of yiqi qingwen jiedu heji on the protein expressions of cytokine IFN-g, TNF-alpha, IL-10 and IL-6 in the lungs of mice infected by IV FM1. Zhongguo Zhong Yao Za Zhi 2005;30:541-544
33. Utsunomiya T, Kobayashi M, Pollard RB, Suzuki F. Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. Antimicrob Agents Chemother 1997;41:551-556
34. Mollica L, De Marchis F, Spitaleri A, Dallacosta C, Pennacchini D, Zamai M, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007;14: 431-441
35. Wang HC, Bloom O, Zhang MH, Vishnubhakat JM, Ombrellino M, Che JT, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-251
36. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420: 885-891
37. Wang H, Li W, Li J, Rendon Mitchell B, Ochani M, Ashok M, et al. The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J Nutr 2006;136:360-365
38. Czura CJ, Wang H, Tracey KJ. Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001;7:315-321
39. Yang H, Wang HC, Tracey KJ. HMG-1 rediscovered as a cytokine. Shock 2001;15:247-253
40. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;192:565-570
41. Chao JC, Wan XS, Engelsberg BN, Rothblum LI, Billings PC. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. Biochim Biophys Acta 1996;7:213-219
42. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, et al. RAGE is the major receptor for the proinflamma- tory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005;61:1-9.
43. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279:7370-7377
44. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995;107: 1062-1073
45. Sunden Cullberg J, Norrby Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005;33:564-573
46. Li W, Li J, Ashok M, Wu R, Chen D, Yang L, et al. A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J Immunol 2007;178:3856-3864
47. Wu BW, Pan TL, Leu YL, Chang YK, Tai PJ, Lin KH, et al. Antiviral effects of Salvia miltiorrhiza (Danshen) against enterovirus 71. Am J Chin Med 2007;35:153-168
48. Zhou Z, Zhang Y, Ding XR, Chen SH, Yang J, Wang XJ, et al. Protocatechuic aldehyde inhibits hepatitis B virus replication both in vitro and in vivo. Antiviral Res 2007;74:59-64.
49. Aldieri E, Atragene D, Bergandi L, Riganti C, Costamagna C, Bosia A, et al. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett 2003; 552:141-144
50. Wang J, Zhou H, Zheng J, Cheng J, Liu W, Ding G, et al. The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing pro- inflammatory cytokine release. Antimicrob Agents Chemother 2006;50:2420-2427
51. Yoshimura A, Kuroda K, Kawasaki K, Yamashina S, Maeda T, Ohnishi S. Infectious cell entry mechanism of influenza virus. J Virol 1982;43:284-293
52. Ertel W, Morrison MH, Ayala A, Chaudry IH. Chloroquine attenuates hemorrhagic shock-induced suppression of Kupffer cell antigen presentation and major histocompatibility complex class II antigen expression through blockade of tumor necrosis factor and prosta- glandin release. Blood 1991;78:1781-1788
53. Ahn JY, Choi IS, Shim JY, Yun EK, Yun YS, Jeong G, et al. The immunomodulator ginsan induces resistance to experimental sepsis by inhibiting Toll-like receptor-mediated inflammatory signals. Eur J Immunol 2006;36:37-45.
54. Ahn JY, Song JY, Yun YS, Jeong G, Choi IS. Protection of Staphylococcus aureus-infected septic mice by suppression of early acute inflammation and enhanced antimicrobial activity by ginsan. FEMS Immunol Med Microbiol 2006;46:187-197
55. Lim DS, Bae KG, Jung IS, Kim CH, Yun YS, Song JY. Anti-septicaemic effect of polysaccharide from Panax ginseng by macrophage activation. J Infect 2002;45:32-38
56. Rendon Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H, et al. IFN-g Induces High Mobility Group Box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003;170: 3890-3897
57. Chen X, Li W, Wang H. More tea for septic patients?-green tea may reduce endotoxin-induced release of high mobility group box 1 and other pro-inflammatory cytokines. Med Hypotheses 2006;66: 660-663
58. Talukdar R, Saikia N, Singal DK, Tandon R. Chronic pancreatitis: evolving paradigms. Pancreatology 2006;6:440-449
59. Bhatia M, Brady M, Shokuhi S, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol 2000;190:117-125
60. Makhija R, Kingsnorth AN. Cytokine storm in acute pancreatitis. J Hepatobiliary Pancreat Surg 2002;9:401-410
61. Yasuda T, Ueda T, Takeyama Y, Shinzeki M, Sawa H, Nakajima T, et al. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas 2006;33:359-363
62. Zhang XP, Li ZJ, Liu DR. Progress in research into the mechanism of Radix salviae miltiorrhizae in treatment of acute pancreatitis. Hepatobiliary Pancreat Dis Int 2006;5:501-504
63. Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflam- matory cytokine activity after menopause. Endocr Rev 2002;23:90-119.
64. Shen P, Liu MH, Ng TY, Chan YH, Yong EL. Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARa, PPARg, and adipocyte differentiation in vitro. J Nutr 2006;136:899-905.
65. Chen HQ, Jin ZY, Li GH. Biochanin A protects dopaminergic neurons against lipopolysaccharide-induced damage through inhibition of microglia activation and proinflammatory factors generation. Neurosci Lett 2007;29:29.
66. Aldridge JR Jr, Moseley CE, Boltz DA, Negovetich NJ, Reynolds C, Franks J, et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci USA 2009;106:5306-5311
67. Ahn KS, Noh EJ, Zhao HL, Jung SH, Kang SS, Kim YS. Inhibition of inducible nitric oxide synthase and cyclooxygenase II by Platycodon grandiflorum saponins via suppression of nuclear factor-kB activation in RAW 264.7 cells. Life Sci 2005;76: 2315-2328
68. Kim JK, Oh SM, Kwon HS, Oh YS, Lim SS, Shin HK. Anti- inflammatory effect of roasted licorice extracts on lipopolysacchar- ide-induced inflammatory responses in murine macrophages. Biochem Biophys Res Commun 2006;345:1215-1223, Epub 2006 May 1215.
69. Kwon HM, Choi YJ, Choi JS, Kang SW, Bae JY, Kang IJ, et al. Blockade of cytokine-induced endothelial cell adhesion molecule expression by licorice isoliquiritigenin through NF-kB signal disruption. Exp Biol Med (Maywood) 2007;232:235-245
70. Surh YJ, Lee JY, Choi KJ, Ko SR. Effects of selected ginsenosides on phorbol ester-induced expression of cyclooxygenase-2 and activation of NF-kB and ERK1/2 in mouse skin. Ann NY Acad Sci 2002;973:396-401.
71. Alleva LM, Yang H, Tracey KJ, Clark IA. High mobility group box 1 (HMGB1) protein: possible amplification signal in the pathogenesis of falciparum malaria. Trans R Soc Trop Med Hyg 2005;99:171-174
72. Karlsson S, Pettila V, Tenhunen J, Laru-Sompa R, Hynninen M, Ruokonen E. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med 2008;34:1046-1053 (Pubitemid 351903793)
73. Alleva LM, Budd AC, Clark IA. Systemic release of high mobility group box 1 protein during severe murine influenza. J Immunol 2008;181:1454-1459
74. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002;99:12351-12356
75. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004;101: 296-301.
76. Abeyama K, Stern DM, Ito Y, Kawahara K, Yoshimoto Y, Tanaka M, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflamma- tory mechanism. J Clin Invest 2005;115:1267-1274
77. Boehme MW, Werle E, Kommerell B, Raeth U. Serum levels of adhesion molecules and thrombomodulin as indicators of vascular injury in severe Plasmodium falciparum malaria. Clin Invest 1994;72:598-603.
78. Boldt J, Wollbruck T, Sonneborn S, Welters A, Hempelmann G. Thrombomodulin in intensive care patients. Intensive Care Med 1995;21:645-650
79. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Cytokines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Thromb Res 1995;80:519-526
80. Keller TT, van der Sluijs KF, de Kruif MD, Gerdes VE, Meijers JC, Florquin S, et al. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res 2006;99:1261-1269
81. Ito T, Kawahara K, Nakamura T, Yamada S, Abeyama K, Hashiguchi T, et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost 2007;5:109-116
82. Esmon C. Do-all receptor takes on coagulation, inflammation. Nat Med 2005;11:475-477
83. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006;1:49-60.
84. Chen X, Wu T, Liu G. Chinese medicinal herbs for influenza: a systematic review. J Altern Complement Med 2006;12:171-180
85. Chen XY, Wu TX, Liu GJ, Wang Q, Zheng J, Wei J, et al. Chinese medicinal herbs for influenza. Cochrane Database Syst Rev 2009;doi:10.1002/14651858. CD004559.pub3.
86. Chang I. Initiative for developing evidence-based standardization of traditional chinese medical therapy in the western pacific region of the World Health Organization. eCAM 2004;1:337-341
87. Lee N, Wong CK, Chan PK, Lun SW, Lui G, Wong B, et al. Hypercytokinemia and hyperactivation of phospho-p38 mitogen- activated protein kinase in severe human influenza A virus infection. Clin Infect Dis 2007;45:723-731
88. Lau JT, Leung PC, Wong EL, Fong C, Cheng KF, Zhang SC, et al. The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life: a prospective cohort study. J Altern Complement Med 2005;11: 49-55.
89. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405: 458-462
90. Huston JM, Gallowitsch Puerta M, Ochani M, Ochani K, Yuan R, Rosas Ballina M, et al. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med 2007;35:2762-2768
91. Kavoussi B, Ross BE. The neuroimmune basis of anti- inflammatory acupuncture. Integr Cancer Ther 2007;6:251-257
92. Chen LC, Yeh TM, Wu HN, Lin YY, Shyu HW. Dengue virus infection induces passive release of high mobility group box 1 protein by epithelial cells. J Infect 2008;56:143-150
93. Rodgers BC, Mims CA. Influenza virus replication in human alveolar macrophages. J Med Virol 1982;9:177-184
94. Hennet T, Ziltener HJ, Frei K, Peterhans E. A kinetic study of immune mediators in the lungs of mice infected with influenza A virus. J Immunol 1992;149:932-939
95. Julkunen I, Melen K, Nyqvist M, Pirhonen J, Sareneva T, Matikainen S. Inflammatory responses in influenza A virus infection. Vaccine 2000;19(Suppl 1):S32-7.
96. Van Reeth K. Cytokines in the pathogenesis of influenza. Vet Microbiol 2000;74:109-116
97. Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 2009;15:277-284
98. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995;270:25752-25761
99. Wang H, Ward MF, Fan XG, Sama AE, Li W. Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol 2006;19:3-9.
100. van Zoelen MA, van der Sluijs KF, Achouiti A, Florquin S, Braun-Peter JM, Yang H, et al. Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia. Virology 2009;391:265-273
101. Wang JY, Guo JS, Li H, Liu SL, Zern MA. Inhibitory effect of glycyrrhizin on NF-KB binding activity in CCl4- plus ethanol- induced liver cirrhosis in rats. Liver 1998;18:180-185
102. Takei H, Baba Y, Hisatsune A, Katsuki H, Miyata T, Yokomizo K, et al. Glycyrrhizin inhibits interleukin-8 production and nuclear factor-kB activity in lung epithelial cells, but not through glucocorticoid receptors. J Pharmacol Sci 2008;106: 460-468
103. Matsui S, Matsumoto H, Sonoda Y, Ando K, Aizu-Yokota E, Sato T, et al. Glycyrrhizin and related compounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line. Int Immunopharmacol 2004;4: 1633-1644
104. Xie CH, Zhang MS, Zhou YF, Han G, Cao Z, Zhou FX, et al. Chinese medicine Angelica sinensis suppresses radiation-induced expression of TNF-alpha and TGF-beta1 in mice. Oncol Rep 2006;15:1429-1436
105. Chao WW, Kuo YH, Li WC, Lin BF. The production of nitric oxide and prostaglandin E2 in peritoneal macrophages is inhibited by Andrographis paniculata, Angelica sinensis and Morus alba ethyl acetate fractions. J Ethnopharmacol 2009;122:68-75.
106. Jang SI, Kim HJ, Kim YJ, Jeong SI, You YO. Tanshinone IIA inhibits LPS-induced NF-kB activation in RAW 264.7 cells: possible involvement of the NIK-IKK, ERK1/2, p38 and JNK pathways. Eur J Pharmacol 2006;542:1-7.
107. Zhang X, Liu D, Wu D, Zhu C, Ye J, Wang K, et al. Effect of salvia miltiorrhizae on the expressions of TLR4 protein in the liver of rats with SAP or OJ. Inflammation 2009;32:151-162
108. Lee KH, Choi EM. Biochanin A stimulates osteoblastic differentiation and inhibits hydrogen peroxide-induced production of inflammatory mediators in MC3T3-E1 cells. Biol Pharm Bull 2005;28:1948-1953
109. Kalayciyan A, Orawa H, Fimmel S, Perschel FH, Gonzalez JB, Fitzner RG, et al. Nicotine and biochanin A, but not cigarette smoke, induce anti-inflammatory effects on keratinocytes and endothelial cells in patients with Behcet's disease. J Invest Dermatol 2007;127:81-89
110. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997;100:2671-2679
111. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: multiple modifications at multiple levels. Lancet Infect Dis 2007;7:358-368
112. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, et al. Peroxisome proliferator- activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kB and AP-1. J Biol Chem 1999;274: 32048-32054
113. Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N. Inhibition of NF-kB signaling by fenofibrate, a per- oxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 2005;23:323-330
114. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001;169:453-459 (Pubitemid 32536978)
115. Kim SR, Lee KS, Park HS, Park SJ, Min KH, Jin SM, et al. Involvement of IL-10 in peroxisome proliferator-activated receptor g-mediated anti-inflammatory response in asthma. Mol Pharmacol 2005;68:1568-1575
116. Paumelle R, Staels B. Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc Med 2008;18:73-78